SCHEMBL7594380

SCHEMBL7594380

O=S(=O)(Nc1ccc(F)cc1NS(=O)(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.62
▸ NFE2L2 Q16236 1/20 0.62
▸ SLC40A1 Q9NP59 1/20 0.56
▸ MEN1 O00255 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ ERBB2 P04626 1/20 0.51
▸ HSP90AA1 P07900 1/20 0.51
▸ HSP90AB1 P08238 1/20 0.51
▸ CHEK1 O14757 1/20 0.50
▸ CDK8 P49336 1/20 0.50
▸ NEK2 P51955 1/20 0.50
▸ LIMK1 P53667 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6394653 0.88 GRM4 (0.57) KEAP1NFE2L2SLC40A1MEN1TSHR
SCHEMBL5801171 0.88 LMNA (0.61) KEAP1NFE2L2MEN1TSHRKMT2A
SCHEMBL6662688 0.85 KEAP1 (0.57) KEAP1NFE2L2SLC40A1MEN1TSHR
SCHEMBL22315132 0.85 MEN1 (0.67) KEAP1NFE2L2MEN1TSHRKMT2A
SCHEMBL5956006 0.83 KEAP1 (0.58) KEAP1NFE2L2MEN1KMT2A
SCHEMBL3806499 0.82 ACLY (0.69) MEN1KMT2A
SCHEMBL19848609 0.81 SLC40A1 (0.49) KEAP1NFE2L2SLC40A1MEN1TSHR
SCHEMBL7589375 0.81 MEN1 (0.77) KEAP1NFE2L2MEN1TSHRKMT2A
SCHEMBL2067538 0.80 ALDH1A1 (0.68) KEAP1SLC40A1MEN1KMT2A
SCHEMBL7591285 0.80 SLC40A1 (0.59) KEAP1NFE2L2SLC40A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 — — EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 — — WO disclosed
Send feedback